6月龄接种麻疹-腮腺炎-风疹疫苗的免疫原性与儿童发病率:一项随机对照试验的研究方案
该研究为双盲随机对照试验,计划在丹麦招募6500名6月龄婴儿,随机接种常规MMR疫苗或安慰剂,所有婴儿15月龄时按常规接种MMR。共同主要结局为6月龄接种后1个月的免疫原性(斑块减少中和试验)和随机化至12月龄的感染性疾病住院发生率。
要点
- 6月龄接种MMR的免疫原性以接种后1个月斑块减少中和试验评估。
- 随机化至12月龄的感染性疾病住院发生率是另一共同主要结局。
- 所有婴儿15月龄时仍按丹麦儿童免疫规划接种常规MMR。
核心结论
- 该试验旨在评估6月龄接种MMR疫苗的免疫原性及对感染性疾病住院的影响。
研究设计与样本
- 丹麦MMR试验为双盲随机对照试验,2019年3月至2021年12月招募,末例末访2022年2月。
- 共6500名6月龄婴儿随机接受肌内注射常规MMR(M-M-R VaxPro)或安慰剂(仅溶剂)。
- 约10%(N=600)婴儿在随机化时、1个月后及15月龄常规MMR接种后1个月采集血样。
- 随机化时另采集头发、唾液和尿液;随机化后6周对所有参与者进行不良事件访谈。
关键数值与推荐
- 共同主要结局之一为6月龄MMR接种后1个月经斑块减少中和试验评估的免疫原性。
- 另一共同主要结局为随机化至12月龄的感染性疾病住院发生率。
- 所有婴儿按丹麦儿童免疫规划在15月龄接种常规MMR。
临床怎么用
- 若6月龄接种MMR被证实安全有效,可为高收入国家调整MMR接种时机提供证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Measles is a highly contagious and serious infection. Before the introduction of vaccination, measles caused yearly epidemics putting vulnerable children at risk of brain damage and death. Despite safe and cost-effective vaccines, measles remains a leading cause of death in children globally. Due to insufficient vaccine coverage and low levels of in utero transferred antibodies from vaccinated mothers, outbreaks of measles in Denmark and other high-income countries are observed at increasing frequency. The current vaccine was introduced in Denmark in 1987 as a one-shot measles-mumps-rubella vaccine at 15 months, a timing chosen to avoid inhibition of the infant's immune response by maternal antibodies. One generation later, the MMR vaccinated mothers have lower antibody levels compared to the naturally infected, and their infants are already susceptible at 6 months of age or earlier, thus increasing the risk of epidemics. METHODS: The Danish MMR trial is a double-blind randomized clinical trial recruiting between March 2019 and December 2021 with last patient last visit in February 2022. Altogether N = 6500 infants aged 6 months will be randomly assigned to intramuscular vaccination with routine MMR (M-M-R VaxPro) or placebo (solvent only). According to the Danish Childhood vaccination program, all infants will receive a routine MMR vaccination at 15 months of age. At randomization, 1 month later, and 1 month after routine MMR vaccination at 15 months of age, a blood sample is drawn from app. 10% (N = 600) of the population. Additionally, hair, saliva, and urine are sampled at randomization. The co-primary study outcomes are immunogenicity 1 month after MMR vaccination at 6 months of age assessed as plaque-reduction neutralization test, and incidence of infectious disease hospitalizations from randomization to 12 months of age. Six weeks post randomization, all participants are interviewed regarding adverse events. TRIAL REGISTRATION: The trial is registered in the EU Clinical Trials Registry. EudraCT registration number: 2016-001901-18 . Registered on 14 February 2017.
引用
- Vittrup DM, Laursen ACL, Malon M, et al. Measles-mumps-rubella vaccine at 6 months of age, immunology, and childhood morbidity in a high-income setting: study protocol for a randomized controlled trial. Trials. 2020. PMID: 33303011. doi:10.1186/s13063-020-04845-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。